Celator Pharmaceuticals

Our Mission: Improving and Extending the Lives of Patients with Cancer

General CPX-351 CPX-1 CPX-571 Nanoparticle Prodrug Delivery Other

Publications: CPX-571

Manuscripts

Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo | Tardi
et al, Mol Cancer Ther 2009;8 2266-2275

Abstracts
Click abstract title to view poster

	Drug Ratio Dependent Antitumor Activity of Irinotecan and Cisplatin Combinations In Vitro and In Vivo \| Tardi et al, AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology and Clinical Applications 2007, Abstract #C114

	Development and Characterization of a Fixed Ratio Formulation of Cisplatin and Irinotecan: In Vitro and In Vivo Activity Against the Human H460 Lung Carcinoma Model \| Ramsay et al, American Association for Cancer Research (AACR) Annual Meeting 2004, Abstract #548

CombiPlex^® technology is a novel approach that identifies molar ratios of drugs that will deliver a synergistic benefit and locks the desired ratio in a nano-scale drug delivery vehicle that delivers and maintains the ratio in patients with the goal of improving clinical outcomes.

© 2009 Celator Pharmaceuticals, Inc. All rights reserved. Celator®, Celator Pharmaceuticals®, the Celator logo and CombiPlex® are registered trademarks of Celator Pharmaceuticals, Inc. Contact webmaster.